After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services.Nonetheless, innovation is at its peak for the industry, with key spaces like diabetes/obesity, gene therapy, inflammation and neuroscience attracting investor attention. FDA approvals continued at a rapid pace throughout 20 ...